Myeloid-derived suppressor cells in cancer: Current knowledge and future perspectives
Authors:
- 5 September 2024
- journal article
- review article
- Published by Elsevier in International Immunopharmacology
- Vol. 142 (Pt A) , 112949
Abstract
No abstract availableKeywords
Funding Information
- Indian Council of Medical Research
This publication has 275 references indexed in Scilit:
- Elevated circulating myeloid‐derived suppressor cells associated with poor prognosis in B‐cell non‐Hodgkin's lymphoma patientsImmunity, Inflammation and Disease, 2022
- The role of myeloid‐derived suppressor cells in gastrointestinal cancerCancer Communications, 2021
- Circulating myeloid‐derived suppressor cells: An independent prognostic factor in patients with breast cancerJournal of Cellular Physiology, 2018
- TLR8 ligation induces apoptosis of monocytic myeloid-derived suppressor cellsJournal of Leukocyte Biology, 2017
- Hypoxia induces myeloid‐derived suppressor cell recruitment to hepatocellular carcinoma through chemokine (C‐C motif) ligand 26Hepatology, 2016
- Circulating and tumor‐infiltrating myeloid cell subsets in patients with bladder cancerInternational Journal of Cancer, 2011
- IL‐1β regulates a novel myeloid‐derived suppressor cell subset that impairs NK cell development and functionEuropean Journal of Immunology, 2010
- Hierarchy of immunosuppressive strength among myeloid‐derived suppressor cell subsets is determined by GM‐CSFEuropean Journal of Immunology, 2009
- Malignant glioma biology: Role for TGF-? in growth, motility, angiogenesis, and immune escapeMicroscopy Research and Technique, 2001
- Characterization of the role of IL-6 in the progression of prostate cancerThe Prostate, 1999